Nasdaq-listed plasma-based biopharmaceutical company China Biologic Products has received a potential shot in the arm in the form of a $4.6 billion buyout offer, according to a Wednesday press release.
The offer price of $120 per share represents a 16.3% premium to China Biologic’s close of $103.10 on Wednesday.
The company, a leading provider of blood plasma-based therapies in China, received the proposal from a group of six buyers, including Beachhead Holdings and CITIC Capital China Partners, according to the release.
The offer is the second such proposal this week, after New York-listed Chinese car comparison website Bitauto received a similar proposal from internet giant Tencent and its private equity partner Hammer Capital.
Contact reporter Matthew Walsh (firstname.lastname@example.org)